According to an article in the Asco Post, the FDA granted accelerated approval to Merck's KEYTRUDA®, pembrolizumab, for the treatment of metastatic small cell lung cancer (SCLC). The drug targets…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
